<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink">
	
	<front>
		<journal-meta>
			<journal-id journal-id-type="nlm-ta">elife</journal-id>
			<journal-id journal-id-type="hwp">eLife</journal-id>
			<journal-id journal-id-type="publisher-id">eLife</journal-id>
			<journal-title-group>
				<journal-title>eLife</journal-title>
			</journal-title-group>
			<issn pub-type="epub">2050-084X</issn>
			<publisher>
				<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
			</publisher>
		</journal-meta>
		<article-meta>
			<article-id pub-id-type="publisher-id">02565</article-id>
			<article-id pub-id-type="doi">10.7554/eLife.02565</article-id>
			<article-categories>
				<subj-group subj-group-type="display-channel">
					<subject>Research Article</subject>
				</subj-group>
				<subj-group subj-group-type="heading">
					<subject>Epidemiology and Global Health</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>A user-friendly, open-source tool to project impact and cost of diagnostic tests for tuberculosis</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author" corresp="yes" id="author-11420">
					<name>
						<surname>Dowdy</surname>
						<given-names>David W</given-names>
					</name>
					<aff>
						<addr-line>
							<named-content content-type="department">Department of Epidemiology</named-content>
						</addr-line>
						, 
						<institution>Johns Hopkins Bloomberg School of Public Health</institution>
						, 
						<addr-line>
							<named-content content-type="city">Baltimore</named-content>
						</addr-line>
						, 
						<country>United States</country>
						<email>ddowdy@jhsph.edu</email>
					</aff>
					<xref ref-type="fn" rid="conf1"/>
				</contrib>
				<contrib contrib-type="author" id="author-11856">
					<name>
						<surname>Andrews</surname>
						<given-names>Jason R</given-names>
					</name>
					<aff>
						<addr-line>
							<named-content content-type="department">Division of Infectious Diseases, Department of Medicine</named-content>
						</addr-line>
						, 
						<institution>Massachusetts General Hospital</institution>
						, 
						<addr-line>
							<named-content content-type="city">Boston</named-content>
						</addr-line>
						, 
						<country>United States</country>
					</aff>
					<xref ref-type="fn" rid="conf1"/>
				</contrib>
				<contrib contrib-type="author" id="author-11857">
					<name>
						<surname>Dodd</surname>
						<given-names>Peter J</given-names>
					</name>
					<aff>
						<addr-line>
							<named-content content-type="department">School of Health and Related Research</named-content>
						</addr-line>
						, 
						<institution>University of Sheffield</institution>
						, 
						<addr-line>
							<named-content content-type="city">Sheffield</named-content>
						</addr-line>
						, 
						<country>United Kingdom</country>
					</aff>
					<xref ref-type="fn" rid="conf1"/>
				</contrib>
				<contrib contrib-type="author" id="author-11858">
					<name>
						<surname>Gilman</surname>
						<given-names>Robert H</given-names>
					</name>
					<aff>
						<addr-line>
							<named-content content-type="department">Department of International Health</named-content>
						</addr-line>
						, 
						<institution>Johns Hopkins Bloomberg School of Public Health</institution>
						, 
						<addr-line>
							<named-content content-type="city">Baltimore</named-content>
						</addr-line>
						, 
						<country>United States</country>
					</aff>
					<xref ref-type="fn" rid="conf1"/>
				</contrib>
			</contrib-group>
			<contrib-group content-type="section">
				<contrib contrib-type="editor" id="author-1180">
					<name>
						<surname>Sgaier</surname>
						<given-names>Sema</given-names>
					</name>
					<role>Reviewing editor</role>
					<aff>
						<institution>Bill &amp; Melinda Gates Foundation</institution>
						, 
						<country>India</country>
					</aff>
				</contrib>
			</contrib-group>
			<pub-date date-type="pub" publication-format="electronic"><day>04</day><month>06</month><year>2014</year></pub-date><volume>3</volume><elocation-id>e02565</elocation-id>
			<supplementary-material><ext-link xlink:href="elife-02565-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history>
				<date date-type="received">
					<day>17</day>
					<month>02</month>
					<year>2014</year>
				</date>
				<date date-type="accepted">
					<day>31</day>
					<month>05</month>
					<year>2014</year>
				</date>
			</history>
			<permissions>
				<copyright-statement>Copyright Â© 2014, Dowdy et al</copyright-statement>
				<copyright-year>2014</copyright-year>
				<copyright-holder>Dowdy et al</copyright-holder>
				<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/">
					<license-p>
						This article is distributed under the terms of the 
						<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution License</ext-link>
						 permitting unrestricted use and redistribution provided that the original author and source are credited.
					</license-p>
				</license>
			</permissions>
			<abstract>
				<p>Most existing models of infectious diseases, including tuberculosis (TB), do not allow end-users to customize results to local conditions. We created a dynamic transmission model to project TB incidence, TB mortality, multidrug-resistant (MDR) TB prevalence, and incremental costs over five years after scale-up of nine alternative diagnostic strategies including combinations of sputum smear microscopy, Xpert MTB/RIF, microcolony-based culture, and same-day diagnosis. We developed a corresponding web-based interface that allows users to specify local costs and epidemiology.  Full model code - including the ability to change any input parameter - is also included. The impact of improved diagnostic testing was greater for mortality and MDR-TB prevalence than TB incidence, and was maximized in high-incidence, low-HIV settings. More costly interventions generally had greater impact. In settings with little capacity for up-front investment, same-day microscopy had greatest impact on TB incidence and became cost-saving within five years if feasible to deliver at $10/test. In settings where more initial investment was possible, population-level scale-up of either Xpert MTB/RIF or microcolony-based culture offered substantially greater benefits, often averting ten times more TB cases than narrowly-targeted diagnostic strategies at minimal incremental long-term cost. Where containing MDR-TB is the overriding concern, Xpert for smear-positives has reasonable impact on MDR-TB incidence, but at substantial price and little impact on overall TB incidence and mortality. This novel, user-friendly modeling framework improves decision-makers' ability to evaluate the impact of TB diagnostic strategies, accounting for local conditions.</p>
			</abstract>
			<kwd-group kwd-group-type="research-organism">
				<title>Research organism</title>
				<kwd>None</kwd></kwd-group>
		</article-meta>
	</front>
	<back>
		<fn-group content-type="competing-interest">
			<title>Competing interest</title>
			<fn fn-type="conflict" id="conf1">
				<p>The authors declare that no competing interests exist.</p>
			</fn>
		</fn-group>
	</back>
</article>